Fluoroquinolone Antibiotics Classification, Uses and Unwanted side effects The fluoroquinolones really are a relatively new team of antibiotics. Fluoroquinolones were first introduced in 1986, though they are really modified quinolones, a class of antibio

Home | Submit Articles | Login

Number Times Read : 2 Word Count: 770

Stats
Total Articles: 393,563 Total Authors: 41,743 Total Downloads: 2,125,033 Newest Member Mohamed Bozeman

Fluoroquinolone Antibiotics Classification, Uses and Unwanted side effects The fluoroquinolones really are a relatively new team of antibiotics. Fluoroquinolones were first introduced in 1986, though they are really modified quinolones, a class of antibio

Category Rss Feed - http://www.ezarticlesdb.com/rss.php?rss=88

By : Sharifi Rodregez zero times read

Submitted 2012-02-14 01:32:52

The fluoroquinolones are a group of synthetic, broad-spectrum antibacterial agents with bactericidal activity. The parent of your group is nalidixic acid, taken from 1962 by Lescher and colleagues. The first fluoroquinolones were frequently basically because they were the only real orally administered agents readily available for managing serious infections caused by gram-negative organisms, including Pseudomonas species.

The newer fluoroquinolones have a very wider clinical use plus a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. Many of the newer fluoroquinolones have an important aspect in handling community-acquired pneumonia and intra-abdominal infections.

Fluoroquinolones disadvantages:

Tendonitis or tendon rupture
Multiple drug interactions
Not used in youngsters
Newer quinolones produce additional toxicities to the heart which are not found with all the older constituents
Fluoroquinolones advantages:
No-fuss administration
Daily or twice daily dosing
Excellent oral absorption
Excellent tissue penetration
Prolonged half-lives
Significant entry into phagocytic cells
Efficacy
Overall safety

Classification of Fluoroquinolones
As a group, the fluoroquinolones have excellent in vitro activity against a wide variety of both gram-positive and gram-negative bacteria. The latest fluoroquinolones have enhanced activity against gram-positive bacteria with just the a small decrease in activity against gram-negative bacteria. Their expanded gram-positive activity is especially important because it includes significant activity against Streptococcus pneumoniae.

First Generation. The first-generation agents include cinoxacin and nalidixic acid, comprehending the oldest and least often used quinolones. These drugs had poor systemic distribution and limited activity and were used primarily for gram-negative urinary tract infections. Cinoxacin and nalidixic acid require more frequent dosing than the newer quinolones, and they're more susceptible into the development of bacterial resistance.

Second Generation. The second-generation fluoroquinolones have increased gram-negative activity, in addition to some gram-positive and atypical pathogen coverage. In comparison to first-generation quinolones, these drugs have broader clinical applications throughout treatment of complicated urinary tract infections and pyelonephritis, stds, selected pneumonias and skin infections.

Second-generation agents include ciprofloxacin, enoxacin, lomefloxacin, norfloxacin and ofloxacin. Ciprofloxacin will be the most potent fluoroquinolone against P. aeruginosa. Ciprofloxacin and ofloxacin will be the most favored second-generation quinolones owing to their availability in oral and intravenous formulations and also their broad group of FDA-labeled indications.

Third Generation. The third-generation fluoroquinolones are separated inside third class due to expanded activity against gram-positive organisms, particularly penicillin-sensitive and penicillin-resistant S. pneumoniae, and atypical pathogens such as Mycoplasma pneumoniae and Chlamydia pneumoniae. While the third-generation agents retain broad gram-negative coverage, they are less active than ciprofloxacin against Pseudomonas species.

Due to expanded antimicrobial spectrum, third-generation fluoroquinolones are helpful throughout remedy for community-acquired pneumonia, acute sinusitis and acute exacerbations of chronic bronchitis, which you ll find are their primary FDA-labeled indications. The third-generation fluoroquinolones include levofloxacin, gatifloxacin, moxifloxacin and sparfloxacin.

Fourth Generation. The fourth-generation fluoroquinolones add significant antimicrobial activity against anaerobes while maintaining the gram-positive and gram-negative activity of the third-generation drugs. They also retain activity against Pseudomonas species comparable to that of ciprofloxacin. The fourth-generation fluoroquinolones include trovafloxacin (Trovan).

Owing to concern about hepatotoxicity, trovafloxacin therapy ought to be kept for life- or limb-threatening infections requiring inpatient treatment (hospital or long-term care facility), and also the drug is needed to be taken for no longer than 14 days.

Negative effects

The fluoroquinolones as a thoughtful class quite some time well tolerated. Most adverse reactions are mild in severity, self-limited, and occasionally set off treatment discontinuation. However, they will be able to have serious uncomfortable side effects.

Fluoroquinolones are approved for use only in people older than 18. They will be able to affect the expansion of bones, teeth, and cartilage within a child or fetus. The FDA has assigned fluoroquinolones to pregnancy risk category C, indicating these drugs have the prospect to cause teratogenic or embryocidal effects. Giving fluoroquinolones when you are pregnant is not really recommended unless the rewards justify inpending risks to the fetus. These agents may also be excreted in breast milk and may be bypassed during breast-feeding if it is possible.

Gastrointestinal effects. The biggest commonplace side effects experienced with fluoroquinolone administration are gastrointestinal (nausea, vomiting, diarrhea, constipation, and abdominal pain), which occur in one to 5% of patients.
CNS effects. Headache, dizziness, and drowsiness seem to have been reported with all fluoroquinolones. Insomnia was reported in 3-7% of patients with ofloxacin. Severe CNS effects, including seizures, have already been reported in patients receiving trovafloxacin. Seizures may develop within three or four times of therapy but resolve with drug discontinuation. Although seizures are infrequent, fluoroquinolones really should be avoided in patients that has a roots or history of convulsion, cerebral trauma, or anoxia. No seizures have been reported with levofloxacin, moxifloxacin, gatifloxacin, and gemifloxacin. Together with the older non-fluorinated quinolones neurotoxic symptoms such as dizziness happened in about 50% of the patients.
Phototoxicity. Skill at ultraviolet A rays from directly or indirectly sunlight should be avoided during treatment and several other days (5 days with sparfloxacin) when by using prescription. The degree of phototoxic potential of fluoroquinolones is just as follows: lomefloxacin > sparfloxacin > ciprofloxacin > norfloxacin = ofloxacin = levofloxacin = gatifloxacin = moxifloxacin.
Musculoskeletal effects. Bother about the creation of musculoskeletal effects, evident in animal studies, has led into the contraindication of fluoroquinolones for routine use in children whereas in the women who are pregnant or lactating.
Tendon damage (tendinitis and tendon rupture). Although fluoroquinolone-related tendinitis generally resolves within 1 week of discontinuation of therapy, spontaneous ruptures have been reported provided nine months after cessation of fluoroquinolone use. Potential risk factors for tendinopathy include age >50 years, male gender, and concomitant use of corticosteroids.
Hepatoxicity. Trovafloxacin use continues to be associated with rare liver damage, which prompted the withdrawal of a typical oral preparations from the U.S. market. However, the IV preparation continues to be readily available for remedy for infections so serious the fact that benefits outweigh the risks.
Cardiovascular effects. The newer quinolones seem to have been found to produce additional toxicities towards the heart that were not found with the older compounds. Evidence suggests that sparfloxacin and grepafloxacin could have by far the most cardiotoxic potential.
Hypoglycemia/Hyperglycemia. Recently, rare cases of hypoglycemia are actually reported with gatifloxacin and ciprofloxacin in patients also receiving oral diabetic medications, primarily sulfonylureas. Although hypoglycemia has been reported with other fluoroquinolones (levofloxacin and moxifloxacin), the effects have been mild.
Hypersensitivity. Hypersensitivity reactions occur hardly ever during quinolone therapy and tend to be mild to moderate in severity, and usually resolve after treatment is stopped.

Conditions treated with Fluoroquinolones: indications and uses
The newer fluoroquinolones have a wider clinical use along with a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. Many of the newer fluoroquinolones contain an important function in treating community-acquired pneumonia and intra-abdominal infections. The serum elimination half-life of many fluoroquinolones diverge from 3 -20 hours, granting maybe once or twice daily dosing.

Author Resource:- The fluoroquinolones certainly are an order of synthetic, broad-spectrum antibacterial agents with bactericidal activity. The parent of a typical group is nalidixic acid, sourced out of 1962 by Lescher and colleagues. The first fluoroquinolones were frequently basically because they were the one orally administered agents readily available for managing serious infections because of gram-negative organisms, including Pseudomonas species. The newer fluoroquinolones have a wider clinical use plus a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. A few of the newer fluoroquinolones have an important aspect in handling community-acquired pneumonia and intra-abdominal infections. Fluoroquinolones disadvantages: Tendonitis or tendon rupture Multiple drug interactions Not used in children Newer quinolones produce additional toxicities towards the heart which are not found with all the older agents Fluoroquinolones advantages: Ease in administration Daily or twice daily dosing Excellent oral absorption Excellent tissue penetration Prolonged half-lives Significant entry into phagocytic cells Efficacy Overall safety Classification of Fluoroquinolones As a thoughtful group, the fluoroquinolones have excellent in vitro activity against a large variety of both gram-positive and gram-negative bacteria. The present fluoroquinolones have enhanced activity against gram-positive bacteria with only a small lowering of activity against gram-negative bacteria. Their expanded gram-positive activity is especially important since it includes significant activity against Streptococcus pneumoniae. First Generation. The first-generation agents include cinoxacin and nalidixic acid, which are the oldest and least often used quinolones. These drugs had poor systemic distribution and limited activity and were put to use primarily for gram-negative urinary tract infections. Cinoxacin and nalidixic acid require more frequent dosing in comparison to the newer quinolones, and they are more susceptible towards the development of bacterial resistance. Second Generation. The second-generation fluoroquinolones have increased gram-negative activity, and also some gram-positive and atypical pathogen coverage. When compared with first-generation quinolones, these drugs have broader clinical applications in the remedy for complicated urinary tract infections and pyelonephritis, sexually transmitted diseases, selected pneumonias and skin infections. Second-generation agents include ciprofloxacin, enoxacin, lomefloxacin, norfloxacin and ofloxacin. Ciprofloxacin is the most potent fluoroquinolone against P. aeruginosa. Ciprofloxacin and ofloxacin will be the most favored second-generation quinolones because of the availability in oral and intravenous formulations as well as their broad range of FDA-labeled indications. Third Generation. The third-generation fluoroquinolones are separated with a third class because of the expanded activity against gram-positive organisms, particularly penicillin-sensitive and penicillin-resistant S. pneumoniae, and atypical pathogens for example Mycoplasma pneumoniae and Chlamydia pneumoniae. Despite the fact that the third-generation agents retain broad gram-negative coverage, they are less active than ciprofloxacin against Pseudomonas species. Owing to their expanded antimicrobial spectrum, third-generation fluoroquinolones are useful inside the treatment of community-acquired pneumonia, acute sinusitis and acute exacerbations of chronic bronchitis, which you ll find are their primary FDA-labeled indications. The third-generation fluoroquinolones include levofloxacin, gatifloxacin, moxifloxacin and sparfloxacin. Fourth Generation. The fourth-generation fluoroquinolones add significant antimicrobial activity against anaerobes while keeping the gram-positive and gram-negative workings of the third-generation drugs. In addition they retain activity against Pseudomonas species comparable to that of ciprofloxacin. The fourth-generation fluoroquinolones include trovafloxacin (Trovan). Because of concern about hepatotoxicity, trovafloxacin therapy should be reserved for life- or limb-threatening infections requiring inpatient treatment (hospital or long-term care facility), along with the drug is needed to be taken for not any longer than 14 days. Negative effects The fluoroquinolones as a thoughtful class is usually well tolerated. Most adverse effects are mild in severity, self-limited, and rarely result in treatment discontinuation. However, they often have serious negative effects. Fluoroquinolones are approved for use only in people older than 18. They can affect the increase of bones, teeth, and cartilage within a child or fetus. The FDA has assigned fluoroquinolones to pregnancy risk category C, indicating that these drugs have the prospect to cause teratogenic or embryocidal effects. Giving fluoroquinolones while pregnant is not recommended unless the benefits justify the possible risks into the fetus. These agents are also excreted in breast milk and should be bypassed during breast-feeding if it is possible. Gastrointestinal effects. The most common negative effects acquainted with fluoroquinolone administration are gastrointestinal (nausea, vomiting, diarrhea, constipation, and abdominal pain), which occur in 1 to 5% of patients. CNS effects. Headache, dizziness, and drowsiness are actually reported with all fluoroquinolones. Insomnia was reported in 3-7% of patients with ofloxacin. Severe CNS effects, including seizures, are actually reported in patients receiving trovafloxacin. Seizures may develop within three to four days of therapy but resolve with drug discontinuation. Although seizures are infrequent, fluoroquinolones should be avoided in patients with a history of convulsion, cerebral trauma, or anoxia. No seizures have already been reported with levofloxacin, moxifloxacin, gatifloxacin, and gemifloxacin. Together with the older non-fluorinated quinolones neurotoxic symptoms similar to dizziness occurred in about 50% of the patients. Phototoxicity. Skill at ultraviolet A rays from directly or indirectly sunlight really should be avoided during treatment and a few days (5 days with sparfloxacin) as the use of clonazepam. The degree of phototoxic potential of fluoroquinolones is just as follows: lomefloxacin > sparfloxacin > ciprofloxacin > norfloxacin = ofloxacin = levofloxacin = gatifloxacin = moxifloxacin. Musculoskeletal effects. Bother about the development of musculoskeletal effects, evident in animal studies, has led towards the contraindication of fluoroquinolones for routine use in children and then in women who are pregnant or lactating. Tendon damage (tendinitis and tendon rupture). Although fluoroquinolone-related tendinitis generally resolves within 1 week of discontinuation of therapy, spontaneous ruptures have been reported provided that nine months after cessation of fluoroquinolone use. Potential risk factors for tendinopathy include age >50 years, male gender, and concomitant by using corticosteroids. Hepatoxicity. Trovafloxacin use has long been involved with rare liver damage, which prompted the withdrawal of the oral preparations coming from the U.S. market. However, the IV preparation remains intended for treatment of infections so serious that the benefits outweigh the risks. Cardiovascular effects. The newer quinolones have been found to produce additional toxicities towards the heart that were not found with the older compounds. Evidence means that sparfloxacin and grepafloxacin could have the foremost cardiotoxic potential. Hypoglycemia/Hyperglycemia. Recently, rare cases of hypoglycemia have already been reported with gatifloxacin and ciprofloxacin in patients also receiving oral diabetic medications, primarily sulfonylureas. Although hypoglycemia has long been reported with other fluoroquinolones (levofloxacin and moxifloxacin), the effects are actually mild. Hypersensitivity. Hypersensitivity reactions occur hardly ever during quinolone therapy and are generally mild to moderate in severity, and typically resolve after treatment is stopped. Conditions treated with Fluoroquinolones: indications and uses The newer fluoroquinolones have a very wider clinical use as well as a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. A few of the newer fluoroquinolones posses important aspect in the treatment of community-acquired pneumonia and intra-abdominal infections. The serum elimination half-life of your fluoroquinolones range from 3 -20 hours, granting a couple of times daily dosing.

Article From EzArticlesDb.com

Related Articles

HTML Ready Article. Click on the "Copy" button to copy into your clipboard.

<!DOCTYPE HTML PUBLIC '-//W3C//DTD HTML 4.01 Transitional//EN' 'http://www.w3.org/TR/html4/loose.dtd'><html><head><title>EzArticlesDb.com | Fluoroquinolone Antibiotics Classification, Uses and Unwanted side effects The fluoroquinolones really are a relatively new team of antibiotics. Fluoroquinolones were first introduced in 1986, though they are really modified quinolones, a class of antibio</title></head><body><h3>Fluoroquinolone Antibiotics Classification, Uses and Unwanted side effects The fluoroquinolones really are a relatively new team of antibiotics. Fluoroquinolones were first introduced in 1986, though they are really modified quinolones, a class of antibio</h3> By: Sharifi Rodregez The fluoroquinolones are a group of synthetic, broad-spectrum antibacterial agents with bactericidal activity. The parent of your group is nalidixic acid, taken from 1962 by Lescher and colleagues. The first fluoroquinolones were frequently basically because they were the only real orally administered agents readily available for managing serious infections caused by gram-negative organisms, including Pseudomonas species. The newer fluoroquinolones have a very wider clinical use plus a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. Many of the newer fluoroquinolones have an important aspect in handling community-acquired pneumonia and intra-abdominal infections. Fluoroquinolones disadvantages: Tendonitis or tendon rupture Multiple drug interactions Not used in youngsters Newer quinolones produce additional toxicities to the heart which are not found with all the older constituents Fluoroquinolones advantages: No-fuss administration Daily or twice daily dosing Excellent oral absorption Excellent tissue penetration Prolonged half-lives Significant entry into phagocytic cells Efficacy Overall safety Classification of Fluoroquinolones As a group, the fluoroquinolones have excellent in vitro activity against a wide variety of both gram-positive and gram-negative bacteria. The latest fluoroquinolones have enhanced activity against gram-positive bacteria with just the a small decrease in activity against gram-negative bacteria. Their expanded gram-positive activity is especially important because it includes significant activity against Streptococcus pneumoniae. First Generation. The first-generation agents include cinoxacin and nalidixic acid, comprehending the oldest and least often used quinolones. These drugs had poor systemic distribution and limited activity and were used primarily for gram-negative urinary tract infections. Cinoxacin and nalidixic acid require more frequent dosing than the newer quinolones, and they're more susceptible into the development of bacterial resistance. Second Generation. The second-generation fluoroquinolones have increased gram-negative activity, in addition to some gram-positive and atypical pathogen coverage. In comparison to first-generation quinolones, these drugs have broader clinical applications throughout treatment of complicated urinary tract infections and pyelonephritis, stds, selected pneumonias and skin infections. Second-generation agents include ciprofloxacin, enoxacin, lomefloxacin, norfloxacin and ofloxacin. Ciprofloxacin will be the most potent fluoroquinolone against P. aeruginosa. Ciprofloxacin and ofloxacin will be the most favored second-generation quinolones owing to their availability in oral and intravenous formulations and also their broad group of FDA-labeled indications. Third Generation. The third-generation fluoroquinolones are separated inside third class due to expanded activity against gram-positive organisms, particularly penicillin-sensitive and penicillin-resistant S. pneumoniae, and atypical pathogens such as Mycoplasma pneumoniae and Chlamydia pneumoniae. While the third-generation agents retain broad gram-negative coverage, they are less active than ciprofloxacin against Pseudomonas species. Due to expanded antimicrobial spectrum, third-generation fluoroquinolones are helpful throughout remedy for community-acquired pneumonia, acute sinusitis and acute exacerbations of chronic bronchitis, which you ll find are their primary FDA-labeled indications. The third-generation fluoroquinolones include levofloxacin, gatifloxacin, moxifloxacin and sparfloxacin. Fourth Generation. The fourth-generation fluoroquinolones add significant antimicrobial activity against anaerobes while maintaining the gram-positive and gram-negative activity of the third-generation drugs. They also retain activity against Pseudomonas species comparable to that of ciprofloxacin. The fourth-generation fluoroquinolones include trovafloxacin (Trovan). Owing to concern about hepatotoxicity, trovafloxacin therapy ought to be kept for life- or limb-threatening infections requiring inpatient treatment (hospital or long-term care facility), and also the drug is needed to be taken for no longer than 14 days. Negative effects The fluoroquinolones as a thoughtful class quite some time well tolerated. Most adverse reactions are mild in severity, self-limited, and occasionally set off treatment discontinuation. However, they will be able to have serious uncomfortable side effects. Fluoroquinolones are approved for use only in people older than 18. They will be able to affect the expansion of bones, teeth, and cartilage within a child or fetus. The FDA has assigned fluoroquinolones to pregnancy risk category C, indicating these drugs have the prospect to cause teratogenic or embryocidal effects. Giving fluoroquinolones when you are pregnant is not really recommended unless the rewards justify inpending risks to the fetus. These agents may also be excreted in breast milk and may be bypassed during breast-feeding if it is possible. Gastrointestinal effects. The biggest commonplace side effects experienced with fluoroquinolone administration are gastrointestinal (nausea, vomiting, diarrhea, constipation, and abdominal pain), which occur in one to 5% of patients. CNS effects. Headache, dizziness, and drowsiness seem to have been reported with all fluoroquinolones. Insomnia was reported in 3-7% of patients with ofloxacin. Severe CNS effects, including seizures, have already been reported in patients receiving trovafloxacin. Seizures may develop within three or four times of therapy but resolve with drug discontinuation. Although seizures are infrequent, fluoroquinolones really should be avoided in patients that has a roots or history of convulsion, cerebral trauma, or anoxia. No seizures have been reported with levofloxacin, moxifloxacin, gatifloxacin, and gemifloxacin. Together with the older non-fluorinated quinolones neurotoxic symptoms such as dizziness happened in about 50% of the patients. Phototoxicity. Skill at ultraviolet A rays from directly or indirectly sunlight should be avoided during treatment and several other days (5 days with sparfloxacin) when by using prescription. The degree of phototoxic potential of fluoroquinolones is just as follows: lomefloxacin > sparfloxacin > ciprofloxacin > norfloxacin = ofloxacin = levofloxacin = gatifloxacin = moxifloxacin. Musculoskeletal effects. Bother about the creation of musculoskeletal effects, evident in animal studies, has led into the contraindication of fluoroquinolones for routine use in children whereas in the women who are pregnant or lactating. Tendon damage (tendinitis and tendon rupture). Although fluoroquinolone-related tendinitis generally resolves within 1 week of discontinuation of therapy, spontaneous ruptures have been reported provided nine months after cessation of fluoroquinolone use. Potential risk factors for tendinopathy include age >50 years, male gender, and concomitant use of corticosteroids. Hepatoxicity. Trovafloxacin use continues to be associated with rare liver damage, which prompted the withdrawal of a typical oral preparations from the U.S. market. However, the IV preparation continues to be readily available for remedy for infections so serious the fact that benefits outweigh the risks. Cardiovascular effects. The newer quinolones seem to have been found to produce additional toxicities towards the heart that were not found with the older compounds. Evidence suggests that sparfloxacin and grepafloxacin could have by far the most cardiotoxic potential. Hypoglycemia/Hyperglycemia. Recently, rare cases of hypoglycemia are actually reported with gatifloxacin and ciprofloxacin in patients also receiving oral diabetic medications, primarily sulfonylureas. Although hypoglycemia has been reported with other fluoroquinolones (levofloxacin and moxifloxacin), the effects have been mild. Hypersensitivity. Hypersensitivity reactions occur hardly ever during quinolone therapy and tend to be mild to moderate in severity, and usually resolve after treatment is stopped. Conditions treated with Fluoroquinolones: indications and uses The newer fluoroquinolones have a wider clinical use along with a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. Many of the newer fluoroquinolones contain an important function in treating community-acquired pneumonia and intra-abdominal infections. The serum elimination half-life of many fluoroquinolones diverge from 3 -20 hours, granting maybe once or twice daily dosing. Author Resource:-> The fluoroquinolones certainly are an order of synthetic, broad-spectrum antibacterial agents with bactericidal activity. The parent of a typical group is nalidixic acid, sourced out of 1962 by Lescher and colleagues. The first fluoroquinolones were frequently basically because they were the one orally administered agents readily available for managing serious infections because of gram-negative organisms, including Pseudomonas species. The newer fluoroquinolones have a wider clinical use plus a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. A few of the newer fluoroquinolones have an important aspect in handling community-acquired pneumonia and intra-abdominal infections. Fluoroquinolones disadvantages: Tendonitis or tendon rupture Multiple drug interactions Not used in children Newer quinolones produce additional toxicities towards the heart which are not found with all the older agents Fluoroquinolones advantages: Ease in administration Daily or twice daily dosing Excellent oral absorption Excellent tissue penetration Prolonged half-lives Significant entry into phagocytic cells Efficacy Overall safety Classification of Fluoroquinolones As a thoughtful group, the fluoroquinolones have excellent in vitro activity against a large variety of both gram-positive and gram-negative bacteria. The present fluoroquinolones have enhanced activity against gram-positive bacteria with only a small lowering of activity against gram-negative bacteria. Their expanded gram-positive activity is especially important since it includes significant activity against Streptococcus pneumoniae. First Generation. The first-generation agents include cinoxacin and nalidixic acid, which are the oldest and least often used quinolones. These drugs had poor systemic distribution and limited activity and were put to use primarily for gram-negative urinary tract infections. Cinoxacin and nalidixic acid require more frequent dosing in comparison to the newer quinolones, and they are more susceptible towards the development of bacterial resistance. Second Generation. The second-generation fluoroquinolones have increased gram-negative activity, and also some gram-positive and atypical pathogen coverage. When compared with first-generation quinolones, these drugs have broader clinical applications in the remedy for complicated urinary tract infections and pyelonephritis, sexually transmitted diseases, selected pneumonias and skin infections. Second-generation agents include ciprofloxacin, enoxacin, lomefloxacin, norfloxacin and ofloxacin. Ciprofloxacin is the most potent fluoroquinolone against P. aeruginosa. Ciprofloxacin and ofloxacin will be the most favored second-generation quinolones because of the availability in oral and intravenous formulations as well as their broad range of FDA-labeled indications. Third Generation. The third-generation fluoroquinolones are separated with a third class because of the expanded activity against gram-positive organisms, particularly penicillin-sensitive and penicillin-resistant S. pneumoniae, and atypical pathogens for example Mycoplasma pneumoniae and Chlamydia pneumoniae. Despite the fact that the third-generation agents retain broad gram-negative coverage, they are less active than ciprofloxacin against Pseudomonas species. Owing to their expanded antimicrobial spectrum, third-generation fluoroquinolones are useful inside the treatment of community-acquired pneumonia, acute sinusitis and acute exacerbations of chronic bronchitis, which you ll find are their primary FDA-labeled indications. The third-generation fluoroquinolones include levofloxacin, gatifloxacin, moxifloxacin and sparfloxacin. Fourth Generation. The fourth-generation fluoroquinolones add significant antimicrobial activity against anaerobes while keeping the gram-positive and gram-negative workings of the third-generation drugs. In addition they retain activity against Pseudomonas species comparable to that of ciprofloxacin. The fourth-generation fluoroquinolones include trovafloxacin (Trovan). Because of concern about hepatotoxicity, trovafloxacin therapy should be reserved for life- or limb-threatening infections requiring inpatient treatment (hospital or long-term care facility), along with the drug is needed to be taken for not any longer than 14 days. Negative effects The fluoroquinolones as a thoughtful class is usually well tolerated. Most adverse effects are mild in severity, self-limited, and rarely result in treatment discontinuation. However, they often have serious negative effects. Fluoroquinolones are approved for use only in people older than 18. They can affect the increase of bones, teeth, and cartilage within a child or fetus. The FDA has assigned fluoroquinolones to pregnancy risk category C, indicating that these drugs have the prospect to cause teratogenic or embryocidal effects. Giving fluoroquinolones while pregnant is not recommended unless the benefits justify the possible risks into the fetus. These agents are also excreted in breast milk and should be bypassed during breast-feeding if it is possible. Gastrointestinal effects. The most common negative effects acquainted with fluoroquinolone administration are gastrointestinal (nausea, vomiting, diarrhea, constipation, and abdominal pain), which occur in 1 to 5% of patients. CNS effects. Headache, dizziness, and drowsiness are actually reported with all fluoroquinolones. Insomnia was reported in 3-7% of patients with ofloxacin. Severe CNS effects, including seizures, are actually reported in patients receiving trovafloxacin. Seizures may develop within three to four days of therapy but resolve with drug discontinuation. Although seizures are infrequent, fluoroquinolones should be avoided in patients with a history of convulsion, cerebral trauma, or anoxia. No seizures have already been reported with levofloxacin, moxifloxacin, gatifloxacin, and gemifloxacin. Together with the older non-fluorinated quinolones neurotoxic symptoms similar to dizziness occurred in about 50% of the patients. Phototoxicity. Skill at ultraviolet A rays from directly or indirectly sunlight really should be avoided during treatment and a few days (5 days with sparfloxacin) as the use of clonazepam. The degree of phototoxic potential of fluoroquinolones is just as follows: lomefloxacin > sparfloxacin > ciprofloxacin > norfloxacin = ofloxacin = levofloxacin = gatifloxacin = moxifloxacin. Musculoskeletal effects. Bother about the development of musculoskeletal effects, evident in animal studies, has led towards the contraindication of fluoroquinolones for routine use in children and then in women who are pregnant or lactating. Tendon damage (tendinitis and tendon rupture). Although fluoroquinolone-related tendinitis generally resolves within 1 week of discontinuation of therapy, spontaneous ruptures have been reported provided that nine months after cessation of fluoroquinolone use. Potential risk factors for tendinopathy include age >50 years, male gender, and concomitant by using corticosteroids. Hepatoxicity. Trovafloxacin use has long been involved with rare liver damage, which prompted the withdrawal of the oral preparations coming from the U.S. market. However, the IV preparation remains intended for treatment of infections so serious that the benefits outweigh the risks. Cardiovascular effects. The newer quinolones have been found to produce additional toxicities towards the heart that were not found with the older compounds. Evidence means that sparfloxacin and grepafloxacin could have the foremost cardiotoxic potential. Hypoglycemia/Hyperglycemia. Recently, rare cases of hypoglycemia have already been reported with gatifloxacin and ciprofloxacin in patients also receiving oral diabetic medications, primarily sulfonylureas. Although hypoglycemia has long been reported with other fluoroquinolones (levofloxacin and moxifloxacin), the effects are actually mild. Hypersensitivity. Hypersensitivity reactions occur hardly ever during quinolone therapy and are generally mild to moderate in severity, and typically resolve after treatment is stopped. Conditions treated with Fluoroquinolones: indications and uses The newer fluoroquinolones have a very wider clinical use as well as a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. A few of the newer fluoroquinolones posses important aspect in the treatment of community-acquired pneumonia and intra-abdominal infections. The serum elimination half-life of your fluoroquinolones range from 3 -20 hours, granting a couple of times daily dosing. Article From <a href='http://www.ezarticlesdb.com/'>EzArticlesDb.com</a> </body></html>

Firefox users please select/copy/paste as usual

Rate This Article
Vote to see the results!

Do you like this article?

New Members
	Sign up
	learn more


Nav Menu
	Home
	Login
	Submit Articles
	Submission Guidelines
	Top Articles
	Link Directory
	About Us
	Contact Us
	Privacy Policy
	RSS Feeds

Actions

Print This Article

Add To Favorites

Privacy Policy \| Contact us
Quality Original Free Articles © 2010 - 2012 EzArticlesDb.com - All Rights Reserved.